Back To The Drawing Board For Portola After Merck Returns Betrixaban
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.